Literature DB >> 1322347

Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome.

J C Arnold1, B C Portmann, J G O'Grady, N V Naoumov, G J Alexander, R Williams.   

Abstract

Cytomegalovirus infection is one factor implicated in the cause of the vanishing bile duct syndrome complicating liver transplantation. To further investigate the role of cytomegalovirus in this syndrome, we studied serial liver biopsy material by in situ hybridization for cytomegalovirus DNA using a highly sensitive technique that allows the localization of viral replication. Cytomegalovirus DNA was identified in hepatocytes in 10 of 12 patients with the vanishing bile duct syndrome, 1 of whom had no serological evidence of cytomegalovirus infection. It was also present in all 18 patients with uncomplicated cytomegalovirus infection but was not identified in any of 10 subjects with transplants who had neither complication. Nine of the patients in this series underwent a diagnostic liver biopsy at 1 wk and subsequently had cytomegalovirus infection develop; cytomegalovirus DNA was identified in liver tissue of all nine patients, indicating that cytomegalovirus replication commences at an early stage. In those with uncomplicated cytomegalovirus, infection occurred earlier (p less than 0.05) but was eliminated more quickly (p less than 0.0005), and the number of infected hepatocytes was greater (p less than 0.05) when compared with those with the vanishing bile duct syndrome; in these, cytomegalovirus DNA was detectable until death or retransplantation. Cytomegalovirus DNA was never identified in either biliary or endothelial tissue. These data indicate that the vanishing bile duct syndrome is associated with persistent cytomegalovirus replication within hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322347     DOI: 10.1002/hep.1840160202

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

Review 1.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

Review 2.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

3.  Hepatobiliary Quiz Answers-17 (2016).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2016-05-04

Review 4.  Infections after orthotopic liver transplantation.

Authors:  Mark Pedersen; Anil Seetharam
Journal:  J Clin Exp Hepatol       Date:  2014-07-24

5.  Hepatic alpha-interferon expression in cytomegalovirus-infected liver allograft recipients with and without vanishing bile duct syndrome.

Authors:  J C Arnold; K T Nouri-Aria; J G O'Grady; B C Portmann; G J Alexander; R Williams
Journal:  Clin Investig       Date:  1993-03

Review 6.  Aspects of liver transplant pathology with emphasis on rejection and its mechanisms.

Authors:  D G Wight
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

Review 7.  Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.

Authors:  Javier Bueno; Carmen Ramil; Michael Green
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

8.  Vanishing bile duct syndrome in human immunodeficiency virus infected adults: a report of two cases.

Authors:  Ana Paula Oppenheimer; Christopher Koh; Mary McLaughlin; John C Williamson; Thomas D Norton; Jennifer Laudadio; Theo Heller; David E Kleiner; Kevin P High; Caryn G Morse
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 9.  Cytomegalovirus and chronic allograft rejection in liver transplantation.

Authors:  Liang-Hui Gao; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

Review 10.  Immunobiology of human cytomegalovirus: from bench to bedside.

Authors:  Tania Crough; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.